Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662961 | 1.00 | CYP1A1 (0.43) | CYP1A1CYP1B1CES2CES1PTGS1 | |
| SCHEMBL9723898 | 0.79 | CYP1A1 (0.55) | CYP1A1CYP1B1CES2CES1PTGS1 | |
| SCHEMBL9723895 | 0.79 | CYP1A1 (0.55) | CYP1A1CYP1B1CES2CES1PTGS1 | |
| SCHEMBL15391538 | 0.76 | AHR (0.42) | PTGS1CYP1A2PTGS2 | |
| SCHEMBL29293800 | 0.73 | PTGS1 (0.41) | CYP1A1CYP1B1CES2CES1PTGS1 | |
| SCHEMBL20415222 | 0.71 | MAOB (0.39) | CYP1A1CYP1B1CES2CES1PTGS1 | |
| SCHEMBL20415220 | 0.71 | MAOB (0.39) | CYP1A1CYP1B1CES2CES1PTGS1 | |
| SCHEMBL15392604 | 0.69 | PTGS2 (0.45) | CYP1A1CYP1B1CES2CES1PTGS1 | |
| SCHEMBL7804952 | 0.66 | ALDH1A1 (0.57) | CYP1A1CYP1B1PTGS1MAOBCYP1A2 | |
| SCHEMBL38655535 | 0.66 | CYP1A2 (0.47) | CYP1A1CYP1B1CES2CES1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
| EP-2234488-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077443-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | CYP1A1 43/4885CYP1B1 10/4885CES2 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.